Nilotinib

InformationMiransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.TargetsAkt2 (Cell-free assay): Akt1 (Cell-free assay): Akt3

InformationMiransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.TargetsAkt2 (Cell-free assay): Akt1 (Cell-free assay): Akt3

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively .In VivoMK-0429

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively .In VivoMK-0429

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively .In VivoMK-0429

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively .In VivoMK-0429

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC 50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1 , αvβ3 , αvβ5 , αvβ6 , αvβ8 and α5β1 , respectively .In VivoMK-0429

A potent inhibitor of Aurora A (IC₅₀ = 0.064 nM) that less potently inhibits Aurora B and Aurora C (IC₅₀s =14 and 12 nM, respectively) blocks cell cycle progression and induces apoptosis in a diverse range of human tumor

An inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC₅₀ = 1.18 &microM) over an isogenic control cell line (EC₅₀ = 27.

An inhibitor of Nrf2 (IC50 = 1.9 µM) that blocks downstream target gene expression substantially enhances cytotoxicity in non-small cell lung cancer (NSCLC) cells treated with platinum-based drugs.

An inhibitor of Nrf2 (IC50 = 1.9 µM) that blocks downstream target gene expression substantially enhances cytotoxicity in non-small cell lung cancer (NSCLC) cells treated with platinum-based drugs.

General description Laminin, a 900kD (approx.) complex extracellular glycoprotein, is the most abundant structural and biologically active component present in the basement membranes.